MDCO and NVS Adcom dates set. AEZS raising more cash. Approvals for BMY AZN GSK + updates for MSTX ALKS
Aeterna Zentaris Inc. (NASDAQ: AEZS $1.46) announced that it has commenced another underwritten public offering of common shares and warrants, their third offering in just over five months.
GW Pharmaceuticals plc (Nasdaq: GWPH $38.06) announced the pricing of its follow-on offering of American Depositary Shares, or ADSs, on the NASDAQ Global Market. GW will issue 2,441,110 ADSs on the NASDAQ Global Market at a price of $36.00 per ADS raising gross proceeds of $87.9 million.
ARCA biopharma, Inc. (Nasdaq: ABIO) maintained guidance that they expect to initiate their Phase 2b GENETIC-AF trial comparing Gencaro to Toprol-XL for prevention of atrial fibrillation (AF) in patients with heart failure and reduced left ventricular ejection fraction (HFREF), during 1Q 2014.
Alkermes plc (NASDAQ: ALKS $42.81) provided an update noting that data from their Phase 3 trial of the once-monthly formulation of aripiprazole lauroxil, are due in 1H 2014. In addition, they intend to initiate a Phase 3 trial of ALKS 5461, for the treatment of major depressive disorder (MDD) in patients who have had an inadequate response to standard therapies, in 1Q 2014. They also unveiled aripiprazole lauroxil two-month, a new product candidate addition to its portfolio of atypical antipsychotics for the treatment of schizophrenia.
Mast Therapeutics, Inc. (NYSE MKT: MSTX $0.58) provided an update on their Phase 3 EPIC trial of MST-188 in sickle cell disease. Full enrollment is due to be completed by the end of 2015.
AstraZeneca (NYSE:AZN $58.52) and Bristol-Myers Squibb Company (NYSE:BMY $53.42) announced the FDA has approved Farxiga (dapagliflozin) to improve glycemic control in adults with type 2 diabetes mellitus.